New York State Teachers Retirement System Sells 1,538 Shares of United Therapeutics Corporation $UTHR

New York State Teachers Retirement System lessened its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 3.0% during the first quarter, HoldingsChannel.com reports. The fund owned 49,334 shares of the biotechnology company’s stock after selling 1,538 shares during the quarter. New York State Teachers Retirement System’s holdings in United Therapeutics were worth $29,254,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in UTHR. Wellington Management Group LLP raised its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. Darwin Global Management Ltd. purchased a new stake in United Therapeutics in the third quarter worth approximately $317,617,000. Norges Bank bought a new stake in United Therapeutics in the 4th quarter worth approximately $293,418,000. Avoro Capital Advisors LLC grew its position in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC raised its stake in United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after buying an additional 341,383 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $577.18, for a total transaction of $5,771,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,894,849.68. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 632,718 shares of company stock valued at $356,533,651. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $555.91 on Friday. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The stock has a market cap of $23.60 billion, a P/E ratio of 20.52, a P/E/G ratio of 1.82 and a beta of 0.58. The company has a 50 day simple moving average of $558.34 and a two-hundred day simple moving average of $527.84.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the prior year, the business earned $6.63 EPS. The company’s revenue was down 1.6% compared to the same quarter last year. As a group, equities analysts forecast that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of several research analyst reports. Morgan Stanley set a $516.00 price target on United Therapeutics in a report on Thursday, May 7th. Royal Bank Of Canada cut their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. HC Wainwright upped their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Cantor Fitzgerald increased their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Finally, Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $619.42.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics agreed to acquire Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestone payments. The deal adds Thymmune’s preclinical thymic cell therapy THY-100 and expands UTHR’s regenerative medicine platform, especially for organ transplantation tolerance and related immune disorders. Article Title
• Positive Sentiment: Analysts continue to view UTHR favorably overall, with the stock carrying a Moderate Buy consensus rating. That suggests the market still sees upside support despite recent volatility and insider sales. Article Title
• Neutral Sentiment: CEO Martine A. Rothblatt and EVP Paul Mahon both sold shares this week, which can create a modest overhang for investor sentiment, though these sales were disclosed and do not necessarily signal a change in the company’s fundamentals. Article Title
• Neutral Sentiment: United Therapeutics recently reported quarterly results that missed analyst expectations on both earnings and revenue, so investors may still be weighing the company’s strong long-term growth strategy against softer near-term execution. Article Title

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.